ABSTRACT
Introduction

CD4
+ T cells, responding to a variety of environmental cues, can differentiate into several distinct subsets of Th that confer specific effector functions. Tfh cells are a newly identified CD4 Th subset that can help B cells form GCs and produce classswitched antibodies [1, 2] . Tfh cells produce the signature cytokine IL-21 and express key transcription factors, including BCL6, which is required for the generation, survival, expansion, and function of both murine and human Tfh cells [3] [4] [5] . Whereas overproduction of Tfh cells can lead to autoimmunity [6] , Tfh cells are critical for the proper production of classswitched, high-affinity antibodies against various viral infections or in response to vaccination.
Interestingly, chronic viral infections, such as HIV-1 infection, promote the drastic expansion of Tfh cells, possibly as a result of constant antigenic stimulation [7] [8] [9] . Accumulation of Tfh cells is associated with increased frequency of activated GC B cells [7, 8] and is thought to contribute to the GC hyperplasia and lymphadenopathy during HIV infection. The production of class-switched BnAbs against HIV is thought to be dependent on Tfh cell function during HIV infection [9] . However, despite the fact that increased Tfh cells and GC reactions are observed in HIV patients, Tfh functional capacity is proposed to be dysregulated in viremic HIV-infected subjects that lose their ability to generate properly robust HIVspecific and de novo humoral responses to new infections or vaccinations [9] .
Strikingly, the Tfh cell population in HIV patients contains the highest percentage of CD4 + T cells having HIV DNA [10] , and GC Tfh cells harbor much higher HIV RNA than non-Tfh cells in viremic individuals [10, 11] . These data raise the possibility that Tfh cells may serve as the major CD4 + T cell compartment and reservoir for HIV infection, replication, and production. Indeed, in situ hybridization on LN sections from untreated, HIV-1-infected individuals revealed higher frequencies of HIV-1 RNA (+) cells in GCs [11] . Furthermore, Tfh cells are believed to be the major reservoir of SIV following ART [8, 12] . Consistent with these in vivo findings, ex vivo HIV infection in Tfh cells has demonstrated that Tfh cells are substantially more permissive to HIV infection than non-Tfh cells [10, 11] . Together, these data suggest that Tfh cells are highly susceptible to HIV infection and replication, but the associated molecular mechanisms that may act to favor greater viral infection and replication in this cell subset remain unknown.
BCL6 is a transcriptional repressor that is required for the lineage specification of Tfh cells. Specific deletion of BCL6 in T cells abrogates Tfh cell generation in vivo, whereas enforced expression of BCL6 promotes Tfh cell differentiation [2, 3, 13] . BCL6 consists of a zinc finger DNA-binding domain, a middle repressor domain (RD2), and an N-terminal BTB repressor domain. The BTB domain is responsible for the recruitment of various transcriptional corepressors, including SMRTs, NCOR, and BCOR [14] . Mice engineered to express a BCL6 BTB mutant that cannot bind to SMRT/NCOR/BCOR show impaired GC B cell phenotype development and diminished Tfh generation and function in vivo [15, 16] . Peptide mimics and small molecules that can disrupt the BCL6 BTB domain binding to SMRT/NCOR/BCOR are able to inhibit the BCL6-dependent growth of lymphoma in vitro and in vivo, suggesting that BCL6 BTB domain inhibitors could be useful targets to disrupt certain BCL6 functions for therapeutic interventions [17] .
In this report, we have examined antiviral gene expression in Tfh and non-Tfh effector cells. We found that both murine and human Tfh cells exhibit diminished antiviral ISG expression compared with their counterparts, non-Tfh cells. We found that Tfh cells exhibited diminished sensitivity to type I IFN stimulation, most probably as a result of the direct inhibition of ISG expression by BCL6. We showed that both murine and human Tfh cells exhibit enhanced susceptibility to viral infections. Importantly, inhibition of BCL6 function enhanced ISG expression in Tfh cells and promoted Tfh cell resistance to HIV infection. Our data reveal that the Tfh master transcription factor BCL6 suppresses antiviral resistance in Tfh cells, thereby enhancing their susceptibility to viral infection. 
MATERIALS AND METHODS
Ethics statement
Western blot analysis
Sorted murine Tfh and non-Tfh cells were washed with cold PBS. Cell pellets were lysed in sample lysis buffer (Cell Signaling Technology, Danvers, MA, USA) with a protease inhibitor cocktail (Thermo Fisher Scientific) and incubated on ice for 30 min. Lysed sample was sonicated and centrifuged. Proteins in the supernatants were heat denatured, separated by 4-12% gradient Bis-Tris gel (Thermo Fisher Scientific), and transferred into a nitrocellulose membrane (Bio-Rad Laboratories, Hercules, CA, USA). Membrane was blocked with 5% of non-fat milk in TBST for 1 h at room temperature. After washing with TBST, the membrane was incubated with the following primary antibodies overnight: rabbit anti-BCL6 (Cell Signaling Technology), rabbit anti-IFITM3 (Sigma-Aldrich, St. Louis, MO, USA), and mouse anti-actin (Santa Cruz Biotechnology, Dallas, TX, USA). The 
ChIP assay
Murine total CD4 + T cells isolated from MLNs of X-31-infected mice, or CD4 + T cells cultured under Tfh conditions were used for ChIP assay. In brief, cells were cultured with 100 ng/ml mouse rIFN-a4 (BioLegend) and fixed with 1% formaldehyde. Then cells were lysed by SDS lysis buffer, including 1% SDS, 10 mM EDTA, and 50 mM Tris (pH 8.1). Anti-mouse BCL6 antibody (Clone N-3; Santa Cruz Biotechnology) was used for immunoprecipitation with DNA/protein complexes. After overnight of immunoprecipitation, DNA was purified, and BCL6-binding DNA fragments were measured by real-time PCR with ChIP primers (shown in Table 1 ) for mouse IFITM3 or MX2. Antibody-binding value was normalized by the amount of input DNA.
In vitro T cell culture
Murine bone marrow-derived DCs were generated as described previously [18] . Naïve CD4 + T cells were isolated from WT or BCL6-fl/fl CD4-Cre mice (BCL6 deficient). CD4 + T cells were mixed with DCs at the ratio of 1:10 in the presence of 0.1 mg/ml soluble aCD3 under Tfh condition with rIL-12 (5 ng/ml), rIL-21 (20 ng/ml), anti-IL-2 (20 mg/ml, Clone S4B6; Bio-X-Cell, West Lebanon, NH, USA), and anti-IFN-g antibodies (20 mg/ml, Clone XMG1.2; Bio-X-Cell) for 4 d. T cells were washed and treated with rIFN-a for 6 h for the determination of antiviral genes.
Real-time PCR
RNA was extracted from cells indicated in the text with a Total RNA Miniprep Kit (Sigma-Aldrich). RNA RT and real-time PCR were performed as described previously [18] . Data were generated with the comparative threshold cycle method by normalizing to hypoxanthine phosphoribosyltransferase or GAPDH.
MSCV retroviral expression
Sorted murine Tfh or non-Tfh cells from MLNs of influenza-infected mice were spin -infected with MSCV-IRES-GFP retrovirus at 2500 rpm for 90 min. After retroviral infection, the cells were cultured with 20 U human IL-2 for 2 d. GFP + cells were measured by flow cytometry. In some experiments, cells were precultured with CP or BCL6 inhibitor RI-BPI (Bio-Synthesis, Lewisville TX, USA) for 1 h. HIV-1 NL4-3 viral stock preparation and ex vivo infection. HIV-1 viral stock was prepared as described in our recent report [19] . In brief, viral DNA pNL4-3 (plasmid construct harbering full-length HIV genome NL4-3) was obtained from the NIH AIDS Reagent Program (Germantown, MD, USA).
After expansion (by transformation to DH5a) and purification, pNL4-3 was transfected into human embryonic kidney 293T cells by lipofectamine. Cell-free supernatants, 48 h post-transfection, were collected as infectious virions by centrifugation and followed by passing through a 0.2 mm filter. Viral stocks were stored at 280°C after measuring virus titer using quantitating p24-Gag (HIV-1 core protein) ELISA. HIV-1 infections were carried out by adding 20 ng/ml p24 of virus solutions to the cells and incubating at 37°C for 2 h. Infected cells were cultured in complete RPMI-1640 medium at 37°C, with or without peptide treatment, for 2 or 4 d in various experiments. Viral RNA or p24-Gag was quantitated as a marker of HIV-1 replication.
BCL6 inhibitor peptide RI-BPI, CP, and IFN-a2b. CPs and RI-BPI were synthesized from Bio-Synthesis (Lewisville, TX). IFN-a2b was purchased from R&D Systems (Minneapolis, MN, USA). After sorting, human Tfh cells were treated with 10 mM CP or BCL6 inhibitory peptide RI-BPI in the presence or absence of IFN-a (100 ng/ml) at 37°C for 12 h. In HIV-1 infection experiments, peptides remained in culture during the infection (48 h).
Statistical analysis
Graphs were generated by GraphPad Prism software (GraphPad Software, La Jolla, CA, USA). Statistical significance was evaluated by calculating P values using one-way ANOVA or Student's t test. Significance between the groups was judged based on P , 0.05 (two-tailed).
RESULTS
Diminished ISG antiviral gene expression in Tfh cells
To determine antiviral gene expression in Tfh and non-Tfh cells, we first analyzed ISG expression in a publicized microarray data set of murine Tfh cells (GEO #GSE40068) [20] . We found that compared with non-Tfh cells (CD44 + CXCR5 2 BCL6 2 ), Tfh (CD44 + CXCR5 + BCL6 hi ) cells exhibit diminished expression of a number of ISGs (Fig. 1A) . To confirm these microarray data, we sorted murine Tfh and non-Tfh cells from the draining MLNs of day 8 influenza X-31-infected WT mice. We sorted Tfh cells as CD44 1A ). As expected, Tfh cells expressed higher levels of the transcription factor BCL6 compared with non-Tfh cells (Supplemental Fig. 1A ). We then examined ISG expression in Tfh and non-Tfh cells by quantitative real-time RT-PCR. We found that a number of ISGs, including IFITMs, MX2, and SAMHD1, were lower in Tfh than non-Tfh cells (Fig. 1B) . Western blot analysis confirmed enhanced BCL6 and diminished IFITM3 protein (Fig. 2C) . BCL6 has been shown to regulate Stat1 expression in osteoblasts [21] . However, we found that Tfh and non-Tfh cells showed similar levels of total STAT1 expression (Fig. 2D) . Furthermore, Tfh cells exhibited comparable STAT1 phosphorylation following IFN-a stimulation compared with non-Tfh cells. BCL6 is a transcriptional repressor that can bind directly to specific DNA-binding sequences to repress target gene expression [14] . We reasoned that BCL6 may directly bind to ISG loci to inhibit their expression in Tfh cells. Consistent with this idea, we found that MX2 and IFITM3 loci contain several potential BCL6 binding sites. Indeed, the BCL6 ChIP assay confirmed that BCL6 could bind to these sites, including the promoter and 39 conserved untranslated region ( Fig. 2E and Supplemental Fig.  2 ). Together, these data suggest that BCL6 directly binds to ISG loci to repress their expression.
Inhibition of BCL6 BTB domain activity enhances Tfh cell resistance to viral infection
The BCL6 BTB domain is required for the recruitment of corepressors to inhibit target gene transcription, which can be abrogated by a peptide inhibitor, RI-BPI [17] . To determine whether the BCL6 BTB domain is responsible for the enhanced susceptibility of viral infection in Tfh cells, we infected WT Tfh and non-Tfh cells in the presence of CP or RI-BPI. We found that RI-BPI treatment did not significantly alter T cell CD69 expression and their survival in vitro (Supplemental Fig. 3) . However, RI-BPI treatment decreased the level of retroviral infection of Tfh cells but not of non-Tfh cells (Fig. 3) . These results suggest that the BCL6 BTB domain is responsible for dampening the resistance of Tfh cells to viral infection. factors, including MX2, IFITMs, SAMHD1, and SLFN11 (Fig. 4A ) [9] , which are the ISGs that have been shown to inhibit HIV infection/replication [22, 23] . To confirm these results, we isolated tonsil Tfh and non-Tfh cells from 6 donors. We identified human Tfh cells as CD4 (Fig. 4C) . We have also assessed HIV-1 core protein (p24-Gag) expression levels by intracellular staining with a Gag-specific antibody. Consistent with the viral Gag RNA levels, we observed higher levels of HIV-1 core protein in Tfh cells compared with non-Tfh cells (Fig. 4D) . Notably, in agreement with a previous report [11] , we found that Tfh and non-Tfh cells exhibited comparable expression levels of HIV-1 coreceptors CXCR4 and CCR5 (Supplemental Fig. 4) . Together, these data indicate that human Tfh cells have diminished anti-HIV innate immunity and enhanced susceptibility to HIV infection and replication.
Human Tfh cells exhibit diminished antiviral gene expression and enhanced susceptibility to HIV infection
BCL6 inhibition leads to enhanced anti-HIV gene expression and host resistance to HIV infection
We reasoned that the inhibition of the BCL6 BTB domain function may increase antiviral gene expression in human Tfh cells. To this end, we treated tonsil Tfh cells with RI-BPI in the absence or presence of IFN-a. We found that RI-BPI treatment 
DISCUSSION
In this report, we provided evidence indicating that both murine and human Tfh cells exhibit diminished expression of antiviral ISG ex vivo. We further showed that the Tfh lineage-defining transcription factor BCL6 binds directly to antiviral ISG loci and potentially represses ISG gene expression. Importantly, inhibition of the BCL6 BTB domain function enhanced ISG expression in Tfh cells and increased their resistance to viral infection. Therefore, our results have provided a molecular mechanism by which Tfh cells are prone to HIV/SIV infection and also offer novel insight into developing methods to boost anti-HIV resistance in Tfh cells potentially to decrease HIV cellular reservoirs following ART. HIV and SIV infection is associated with great expansion of Tfh cells in the host [7] [8] [9] . Indeed, Tfh cells were shown to have multifaceted roles during HIV and SIV infection. On one hand they are essential in regulating the development of BnAb responses, and on the other hand, chronic Tfh cell activation may contribute to the immunopathology of HIV and SIV infection. Furthermore, multiple lines of evidence suggest that Tfh cells are highly permissive to HIV or SIV infection in vitro and are major cellular targets of HIV infection in vivo [11, [24] [25] [26] . Previous findings have suggested that HIV-1 chemokine coreceptor expression and Tfh immune activation were not linked to the permissivity of Tfh cells to ex vivo HIV infection [11] . In accordance with these findings, we also found that Tfh cells (or GC-Tfh, as referred to by the other report [11] ) in our tonsil cell populations exhibit comparable expression of CXCR4 and CCR5, suggesting that the enhanced HIV infection and replication are not a result of the differential expression of these two HIV coreceptors.
SAMHD1 is an important HIV restriction factor in CD4 + T cells, and Tfh cells exhibited lower levels of SAMHD1 expression [27] . Likewise, we found that Tfh cells exhibited lower expression of SAMHD1. In addition, we found that murine Tfh cells exhibited impairment in the expression of a variety of antiviral genes downstream of type I IFN, suggesting that Tfh cells have a global defect in innate resistance to viral infection. Consistent with this idea, human Tfh cells exhibit impaired expression of IFITM3, MX2, and SLFN11, 3 major HIV restriction factors identified recently that can block HIV infection and/or replication at various stages. IFITM3 blocks HIV infection, possibly through the disruption of viral fusion [28] [29] [30] , whereas MX2 is a postentry inhibitor of HIV by antagonizing nuclear accumulation of viral cDNAs [31] [32] [33] . SLFN11 is upregulated in HIV-1 elite controllers and is thought to inhibit viral protein synthesis in HIV-infected cells by means of codon-bias discrimination [34, 35] . The relative contributions of impaired expression of SAMHD1, IFITM3, MX2, or SLFN11 in the susceptibility of Tfh cells to HIV infection were not tested in this study. However, BCL6 inhibition failed to augment SAMHD1 expression but still improved Tfh resistance to HIV infection. One possible explanation is that IFITM3, MX2, and/or SLFN11 may supplement SAMHD1 function in this regard. In addition, we did not firmly establish that diminished ISG expression is responsible for the enhanced HIV infection in our study. It is possible that other factors, including the differential activation status of Tfh and non-Tfh, could underlie their differential susceptibility to HIV infection. Further studies are warranted to determine whether Tfh susceptibility to HIV infection is regulated through the impaired expression of a single factor or a combination of multiple factors. Notably, type I IFN treatment inhibits cells to produce infectious HIV virions [36] . Thus, it is of interest to investigate in the future whether Tfh cells are able to produce more infectious virus as a result of their lower levels of ISG expression compared with non-Tfh cells. An interesting question raised from our study is why Tfh cells down-regulate their antiviral gene expression compared with non-Tfh cells. BCL6 was shown to be required for Tfh cell survival [37] . Many ISGs are proapoptotic and/or can arrest the cell cycle to inhibit virus dissemination [38] . Thus, the survival and/or proliferation of Tfh cells may require the function of BCL6 to antagonize expression or function of ISGs. To this end, type I IFN signaling, which leads to the expression of ISGs, has been shown to interfere with both murine and human Tfh cell development and expansion [39, 40] , suggesting that ISGs downstream of IFN signaling could hamper the development or maintenance of Tfh cells. Consistent with the idea, we found that Tfh cells were less capable of up-regulating ISGs following type I IFN treatment. Of note, 1 recent study has shown that the antiapoptotic protein BCL2 expression was enhanced in Tfh cells compared with non-Tfh cells, presumably to help Tfh survival, but may contribute to HIV propagation in B cell follicles in vivo [41] . The relationship and functional intersection of BCL6 and BCL2 in promoting Tfh survival and HIV propagation in vivo require future studies.
Tfr cells are recently identified FOXP3+CXCR5+PD-1+ regulatory T cells that are specialized to control GC antibody responses [42] . As a result of technical challenges of isolating live Tfr cells, we were not able to examine ISG expression in those cells. Given Tfr cells express high levels of BCL6 [42] similar to Tfh cells, it could be possible that Tfr cells exhibit lower ISG expression compared with other effector and/or regulatory cell subsets. This hypothesis warrants future investigations. Interestingly, although BCL6 has been found to regulate STAT1 expression in osteoblasts [21] , we found that Tfh cells exhibited similar levels of type I IFNR and STAT1 and were able to up-regulate similar levels of phosphorylated STAT1 expression when compared with non-Tfh cells. As BCL6 is a transcriptional repressor, we had hypothesized that BCL6 directly inhibits ISG expression in Tfh cells following type I IFN exposure. Consistent with this idea, BCL6 could bind to ISG loci, strongly indicating that its mechanism of action includes direct inhibition of ISG expression in Tfh cells. Genomic studies have revealed that many BCL6-bound loci were found to be present with a STAT-binding motif, suggesting that BCL6 may globally antagonize the functions of STATs [16] . BCL6 may act as a negative-feedback mechanism for type I IFN signaling, as STAT1 can also upregulate BCL6 expression in T cells [43] . Thus, a regulatory balance of STAT1-BCL6 may determine the outcome of ISG expression and its downstream effects on viral susceptibility in Tfh cells. Notably, we did not compare comprehensively the type I IFN downstream signaling events between Tfh cells and nonTfh cells other than STAT1 phosphorylation in our study. Thus, it remains possible that other STAT1-independent defects of type I IFN signaling contribute to the impaired ISG expression in Tfh cells. Such a possibility requires further studies.
BCL6 contains two repressor domains: a middle RD2 and an N-terminal BTB domain [14] . Each of these domains can associate with specific corepressor complexes in B cells and macrophages. Both the RD2 domain and BCL6 BTB domain have been shown to be important in Tfh cell function in vivo [44] [45] [46] . We found that RI-BPI, a peptide inhibitor that can disrupt the association of the BCL6 BTB domain with its corepressors, was able to up-regulate Tfh ISG expression, suggesting the BCL6 BTB domain is critically important in suppressing ISG expression in Tfh cells. A recent report has also suggested that inhibition of the BCL6 BTB domain could boost type I IFN expression in myeloid cells [47] . Thus, the inhibition of the BCL6 BTB domain function may offer a unique opportunity to boost both type I IFN production and sensitivity to type I IFNs in IFN-responding cells. The targeting of BCL6 may be a promising approach to decrease HIV reservoirs in vivo. This possibility clearly deserves further future investigation. analysis. S.K.G. and A.L.D. participated in data analysis. L.J.M., Q.Y., and J.S. participated in research design, data analysis, and the writing of the paper. All authors read and approved the final manuscript.
